{
  "nctId": "NCT01741311",
  "briefTitle": "Secondary HIV Prevention and Adherence Among HIV-infected Drug Users",
  "officialTitle": "Secondary HIV Prevention and Adherence Among HIV-infected Drug Users",
  "protocolDocument": {
    "nctId": "NCT01741311",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2012-07-05",
    "uploadDate": "2025-06-27T12:43",
    "size": 10246088,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT01741311/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 106,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2012-09",
    "completionDate": "2018-06",
    "primaryCompletionDate": "2018-06",
    "firstSubmitDate": "2012-11-30",
    "firstPostDate": "2012-12-04"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* HIV positive\n* Opioid dependent and enrolled in methadone maintenance treatment\n* Report drug- or sex-related HIV risk behavior in previous 6 months\n* Able to read and understand the questionnaires, the Audio Computer Assisted Self Interview (ACASI), and consent form\n* Available for the full duration of the study with no anticipated circumstances impeding participation\n* Not actively suicidal, homicidal, or psychotic as assessed by trained research staff under the supervision of the PI who is a licensed clinical psychologist in Connecticut.\n\nExclusion Criteria:\n\n\\-",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number of Participants in Each Condition With Optimal ART Adherence",
        "description": "Anti-retroviral therapy (ART) adherence was assessed by self-report using the visual analogue scale (VAS). The VAS measures adherence continuously from 0 to 100%, with higher scores indicating better adherence to the medication. A greater number of participants with optimal ART adherence is better. Optimal ART adherence is defined as a score \\>95% on the visual analog scale (VAS).",
        "timeFrame": "Assessed at post-intervention, 3-months, & 6-months. Reported in the table at 6-months."
      }
    ],
    "secondary": [
      {
        "measure": "Viral Suppression",
        "description": "Number of participants in each condition with viral load suppression at the 6-month assessment point. Viral suppression (VS) is defined as someone having HIV-1 RNA\\<50 copies/mL. A greater number of participants with VL suppression is a better outcome.",
        "timeFrame": "Assessed at post-intervention, 3-months, & 6-months. Reported in the table at 6-months."
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 29,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:19.640Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}